Top Device Stories of 2010: A Look Back and a Glance Forward
Executive Summary
This article was adapted from "Top Device Stories of 2010: Waiting for the Other Shoes to Fall," in the January 2011 issue of IN VIVO.
You may also be interested in...
Start-Up News
Noteworthy news from medtech start-ups. This month we profile NinePoint Medical, which is developing technology for real-time diagnosis of esophogeal cancer and e(ye)BRAIN, which aims to diagnose neurological disorders by tracking eye movements. These company profiles first appeared in Start-Up magazine.
Vertebral Compression Fracture Treatments Under Pressure
A decade ago, the treatment of vertebral compression fractures (VCF) represented one of the fastest - and most innovative - segments of a spine industry that was set to explode. The two principal procedures - vertebroplasty and its distant cousin kyphoplasty - presented surgeons and interventionalists with a minimally invasive option to stop pain and, in the case of kyphoplasty, restore the shape and form to a broken vertebra. Now, two studies published in The New England Journal of Medicine suggesting that vertebroplasty procedures were no more effective in relieving pain than a placebo treatment have put pressure on VCF companies and doctors, who are facing pushback on reimbursement and some skepticism from even their own specialists.
TCT 2010: TAVI Takes Center Stage
In the interventional cardiology community, 2010 could certainly be considered a breakthrough year for percutaneous heart valve devices. At two major US cardiology conferences: the American College of Cardiology in the spring, and most recently, the Transcatheter Cardiovascular Therapeutics symposium, held in September, impressive results from randomized trials of transcatheter heart valve replacement/repair devices set the venues abuzz and had physicians speculating about possible near-term paradigm shifts in the way heart valve disease will be treated. The big questions now are how long it will take before these devices reach the US market, and exactly how many US patients are likely to be implanted once they are available.